Article Details
Retrieved on: 2020-12-14 13:30:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The ACTT-2 trial assessed the efficacy and safety of a 4-mg dose of baricitinib with <b>remdesivir</b>, versus <b>remdesivir</b> alone, in hospitalized COVID-19 ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here